DCPH Stock Overview
A biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Deciphera Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$25.48 |
| 52 Week High | US$25.55 |
| 52 Week Low | US$9.90 |
| Beta | 0.20 |
| 1 Month Change | 74.76% |
| 3 Month Change | 61.78% |
| 1 Year Change | 76.09% |
| 3 Year Change | -24.26% |
| 5 Year Change | 3.70% |
| Change since IPO | 44.36% |
Recent News & Updates
Recent updates
Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) 61% Share Price Surge Not Quite Adding Up
Apr 30
Diving Into Deciphera Pharmaceuticals
Apr 26We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Mar 13We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 02Are Investors Undervaluing Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) By 41%?
Sep 25Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Jul 26Calculating The Intrinsic Value Of Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH)
Jun 22Lacklustre Performance Is Driving Deciphera Pharmaceuticals, Inc.'s (NASDAQ:DCPH) Low P/S
May 08We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Apr 10We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Can Afford To Drive Business Growth
Dec 29Deciphera initiated at buy at Cowen on Qinlock growth, pipeline; sees 68% upside
Aug 29Deciphera Pharmaceuticals Q2 2022 Earnings Preview
Aug 03We Think Deciphera Pharmaceuticals (NASDAQ:DCPH) Needs To Drive Business Growth Carefully
Jul 29Deciphera Pharmaceuticals: Not Too Happy With The Risk-Reward Right Now
Feb 11Deciphera Pharmaceuticals: The 75% Haircut Doesn't Seem Justified
Nov 22Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Aug 26Deciphera Pharmaceuticals posts data from cancer studies at ASCO21
Jun 04Companies Like Deciphera Pharmaceuticals (NASDAQ:DCPH) Are In A Position To Invest In Growth
May 10Growth Investors: Industry Analysts Just Upgraded Their Deciphera Pharmaceuticals, Inc. (NASDAQ:DCPH) Revenue Forecasts By 16%
Feb 11
Deciphera Pharmaceuticals (NASDAQ:DCPH) Is In A Good Position To Deliver On Growth Plans
Feb 05Deciphera to expand geographic reach and clinical potential of ripretinib
Jan 11Shareholder Returns
| DCPH | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | 0.07% | -0.2% |
| 1Y | 76.1% | 6.9% | 28.2% |
Return vs Industry: DCPH exceeded the US Biotechs industry which returned 5% over the past year.
Return vs Market: DCPH exceeded the US Market which returned 27.7% over the past year.
Price Volatility
| DCPH volatility | |
|---|---|
| DCPH Average Weekly Movement | 20.9% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 5.9% |
| 10% most volatile stocks in US Market | 16.0% |
| 10% least volatile stocks in US Market | 2.8% |
Stable Share Price: DCPH's share price has been volatile over the past 3 months.
Volatility Over Time: DCPH's weekly volatility has increased from 12% to 21% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2003 | 355 | Steve Hoerter | www.deciphera.com |
Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gastrointestinal stromal tumors (GIST), as well as in INTRIGUE Phase 3 study to treat second-line GIST. The company is also developing vimseltinib, an orally administered, potent, and highly selective switch-control kinase inhibitor of colony stimulating factor 1 receptor (CSF1R) for the treatment of tenosynovial giant cell tumor (TGCT); and DCC-3116 to treat RAS/RAF mutant cancers that is in the preclinical-stage.
Deciphera Pharmaceuticals, Inc. Fundamentals Summary
| DCPH fundamental statistics | |
|---|---|
| Market cap | US$2.20b |
| Earnings (TTM) | -US$190.42m |
| Revenue (TTM) | US$174.91m |
12.6x
P/S Ratio-11.6x
P/E RatioIs DCPH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| DCPH income statement (TTM) | |
|---|---|
| Revenue | US$174.91m |
| Cost of Revenue | US$242.52m |
| Gross Profit | -US$67.61m |
| Other Expenses | US$122.80m |
| Earnings | -US$190.42m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.20 |
| Gross Margin | -38.66% |
| Net Profit Margin | -108.87% |
| Debt/Equity Ratio | 0% |
How did DCPH perform over the long term?
See historical performance and comparison